Specialty Chemicals company Rossari Biotech announced Q1FY26 results Q1FY26 Consolidated Financial Highlights: Revenue from operations grew 11% to Rs 543.7 crore as compared to Rs 489.7 crore. EBITDA improved by 4.6% to Rs 67.9 crore from Rs 64.9 crore. EBITDA margin at 12.5% as against 13.3%. PAT reduced by 3.7% to Rs 33.6 crore from Rs 34.9 crore. EPS (Diluted) stood at Rs 6.1 as against Rs 6.3. Q1FY26 Standalone Financial Highlights: Revenue from operations stood at Rs 365.8 crore as against Rs 300.7 crore, up 21.6%. EBITDA increased by 10.3% to Rs 43.9 crore as against Rs 39.8 crore. EBITDA margin at 12.0% as against 13.2%. PAT higher by 7.8% to Rs 26.2 crore as against Rs 24.3 crore. EPS (Diluted) stood at Rs 4.7 as against Rs 4.4. Edward Menezes, Promoter & Executive Chairman, & Sunil Chari, Promoter & Managing Director, said: “We delivered a steady performance in Q1FY26, with topline growth driven by strong momentum in our HPPC and AHN segments. Despite a challenging and evolving operating environment, our core businesses continued to demonstrate resilience. Though our export business was lower compared to the last quarter, it has shown healthy growth over the last year. While overall growth remained healthy, we are confident that our continued efficiency initiatives and focused efforts on optimising the product mix will continue to drive growth over the coming quarteRs The HPPC and AHN divisions achieved a healthy growth of 16% and 12% respectively, reflecting the dedicated efforts of our team in a challenging operating environment. We continue to expand our customer base which is significantly contributing to our growth story. The HPPC segment remained the primary growth driver, supported by deeper market penetration and traction across agrochemicals, personal care, institutional and consumer business. Our ongoing capacity expansion projects across verticals are progressing in a phased manner, with commissioning scheduled over the coming quarters. These strategic investments are aimed at enhancing manufacturing capabilities, improve supply chain agility, and strengthen our responsiveness to high-growth sectors such as personal care, agrochemicals, oil & gas and pharma. We believe these expansions will play a pivotal role in unlocking meaningful value and driving the next phase of our growth journey. Looking ahead, we remain committed to execution excellence, customer-led innovation, and sustainable value creation. Supported by a robust balance sheet, a strong R&D; foundation, and our ongoing capacity expansion initiatives, we are well-positioned to navigate near-term challenges and deliver consistent, profitable growth for all stakeholders.” Result PDF
Specialty Chemicals company Rossari Biotech announced Q4FY25 & FY25 results Q4FY25 Financial Highllights: Revenue from operations grew 22.6% to Rs 579.6 crore as compared to Rs 472.7 crore. EBITDA improved by 9.3% to Rs 69.5 crore from Rs 63.6 crore. EBITDA margin at 12.0% as against 13.5%. PAT increased by 0.9% to Rs 34.4 crore from Rs 34.1 crore. EPS (Diluted) stood at Rs 6.21 as against Rs 6.17. FY25 Financial Highllights: Revenue from operations stood at Rs 2,080.3 crore as against Rs 1,830.6 crore, up 13.7%. EBITDA increased by 6.1% to Rs 265.1 crore as against Rs 249.8 crore. EBITDA margin at 12.7% as against 13.6%. PAT higher by 4.4% to Rs 136.4 crore as against Rs 130.7 crore. EPS (Diluted) stood at Rs 24.63 as against Rs 23.62. Edward Menezes, Promoter & Executive Chairman, & Sunil Chari, Promoter & Managing Director, said: “We concluded the year with a steady performance, navigating a soft and evolving operating environment. Revenues grew by ~14% driven by healthy export momentum and resilient volumes across key categories. The HPPC segment remained the primary growth driver, supported by deeper market penetration and strong traction across agrochemicals, personal care, institutional and consumer business. The TSC and AHN segments recorded modest revenue growth, contributing positively to the overall performance. We remain optimistic about their medium-to-long-term potential, supported by ongoing portfolio optimization efforts. Export markets continued to perform well during the year, validating our strategic investments in global partnerships and differentiated solutions. We are also encouraged by the growing momentum in emerging verticals such as institutional cleaning and B2C businesses, which reflect our ability to build scalable, value-added platforms aligned with evolving customer needs. We continue to invest in capacity enhancement to strengthen our growth foundation and are pleased to announce an additional capex of Rs 97 crore for expansions at our subsidiaries, Unitop Chemicals and Tristar Intermediates, along with Rs 95 crore at Rossari Biotech. These projects, expected to be commissioned in a phased manner by Q4 FY26, are aimed at supporting growth across our key chemistries, improving operational efficiency, and enhancing supply reliability. Our previously announced expansion projects are progressing well, with commissioning expected by Q2 FY26. With these capacity additions, we are well-positioned to meet growing demand across end-user industries. Looking ahead, we remain focused on delivering sustainable, profitable growth through sharp execution, customer-centric innovation, and strategic diversification. Supported by a strong balance sheet, an agile business model, and a growing global footprint, we are confident in our ability to maintain healthy growth momentum in the coming years.” Result PDF
Conference Call with Rossari Biotech Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Conference Call with Rossari Biotech Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.